SK14342003A3 - Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK14342003A3
SK14342003A3 SK1434-2003A SK14342003A SK14342003A3 SK 14342003 A3 SK14342003 A3 SK 14342003A3 SK 14342003 A SK14342003 A SK 14342003A SK 14342003 A3 SK14342003 A3 SK 14342003A3
Authority
SK
Slovakia
Prior art keywords
alkyl
phenyl
alkoxy
tetrahydro
chloro
Prior art date
Application number
SK1434-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Armin Hatzelmann
Degenhard Marx
Wolfram Steinhilber
Geert Jan Sterk
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of SK14342003A3 publication Critical patent/SK14342003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
SK1434-2003A 2001-04-25 2002-04-23 Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie SK14342003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01110228 2001-04-25
PCT/EP2002/004438 WO2002085906A2 (fr) 2001-04-25 2002-04-23 Phtalazinones

Publications (1)

Publication Number Publication Date
SK14342003A3 true SK14342003A3 (sk) 2004-05-04

Family

ID=8177249

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1434-2003A SK14342003A3 (sk) 2001-04-25 2002-04-23 Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (22)

Country Link
US (1) US7186710B2 (fr)
EP (1) EP1385848A2 (fr)
JP (1) JP2004526789A (fr)
KR (1) KR20040008162A (fr)
CN (1) CN1503792A (fr)
AU (1) AU2002317733B2 (fr)
BG (1) BG108294A (fr)
BR (1) BR0209149A (fr)
CA (1) CA2445233A1 (fr)
CZ (1) CZ299347B6 (fr)
EA (1) EA200301100A1 (fr)
EE (1) EE200300514A (fr)
HR (1) HRP20030868A2 (fr)
HU (1) HUP0303998A3 (fr)
IL (1) IL157908A0 (fr)
MX (1) MXPA03009583A (fr)
NO (1) NO20034773L (fr)
NZ (1) NZ529221A (fr)
PL (1) PL363312A1 (fr)
SK (1) SK14342003A3 (fr)
WO (1) WO2002085906A2 (fr)
ZA (1) ZA200308930B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234634B2 (en) 2001-02-15 2007-07-26 Takeda Gmbh Phthalayinone-piperidino-derivatives as PDE4 inhibitors
CZ20033205A3 (en) * 2001-04-25 2004-03-17 Altana Pharma Ag Piperazino-derivatives and their use as pde4 inhibitor
US7220746B2 (en) * 2002-08-10 2007-05-22 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
EP1556369A1 (fr) * 2002-08-10 2005-07-27 ALTANA Pharma AG Derives de pyridazinone utilises comme inhibiteurs de pde4
WO2004018449A1 (fr) * 2002-08-10 2004-03-04 Altana Pharma Ag Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)
US20060166995A1 (en) * 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
EP1716123A1 (fr) * 2004-02-04 2006-11-02 Altana Pharma AG Derives de pyridazinone utiles comme inhibiteurs de pde4
US7494990B2 (en) * 2004-02-04 2009-02-24 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
KR20070042164A (ko) * 2004-07-05 2007-04-20 아스텔라스세이야쿠 가부시키가이샤 피라졸로피리딘 유도체
CN101163681A (zh) * 2005-04-21 2008-04-16 日本新药株式会社 2,3-二氮杂萘酮衍生物及其医药品
ES2308916B1 (es) 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (fr) * 2007-03-27 2016-11-22 Omeros Corporation Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
PL2148876T3 (pl) 2007-05-16 2012-02-29 Takeda Gmbh Pochodne pirazolonu jako inhibitory PDE4
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
US8653098B2 (en) 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
LT2672957T (lt) 2011-02-07 2017-02-10 Scipharm Sarl Naujoji kompozicija, skirta cistinės fibrozės gydymui
BR112013031791A2 (pt) * 2011-06-17 2017-01-31 Takeda Gmbh derivados de ftalazinona-pirrolopirimidinacarboxamida
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN102964340B (zh) * 2012-12-12 2015-10-07 中国药科大学 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
CN112876460B (zh) * 2021-02-05 2022-05-31 山西大学 7-二乙胺基-3-乙酰基香豆素衍生物及其合成方法和应用
WO2024038089A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716954A (en) 1991-10-09 1998-02-10 Syntex U.S.A. Inc. Benzopyridazinone and pyridopyridazinone compounds
TW365606B (en) * 1991-10-09 1999-08-01 Syntex Inc Pyrido pyridazinone and pyridazinthione compounds
NZ257955A (en) 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
SK283270B6 (sk) 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
ATE258930T1 (de) 1997-12-15 2004-02-15 Altana Pharma Ag Dihydrobenzifurane
WO1999031071A1 (fr) * 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux phtalazinones
EP0934933A1 (fr) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phtalazinones
PT1070056E (pt) * 1998-03-14 2004-11-30 Altana Pharma Ag Inibidores de pde iii/iv a base de ftalazinona
AU7654200A (en) 1999-09-14 2001-04-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
TR200201128T2 (tr) 1999-10-25 2002-08-21 Byk Gulden Lomberg Chemische Fabrik Gmbh PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
CA2388121A1 (fr) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Derives de phthalazinone, utilises comme inhibiteurs de pde4
SK17052002A3 (sk) 2000-06-05 2003-12-02 Altana Pharma Ag Pyridazinónové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
WO2002085906A2 (fr) 2002-10-31
EA200301100A1 (ru) 2004-06-24
CZ20033206A3 (cs) 2004-02-18
AU2002317733B2 (en) 2007-12-13
EP1385848A2 (fr) 2004-02-04
IL157908A0 (en) 2004-03-28
ZA200308930B (en) 2004-06-09
MXPA03009583A (es) 2004-02-12
WO2002085906A3 (fr) 2002-12-19
HRP20030868A2 (en) 2005-08-31
US20040127707A1 (en) 2004-07-01
KR20040008162A (ko) 2004-01-28
HUP0303998A3 (en) 2007-03-28
NO20034773D0 (no) 2003-10-24
NO20034773L (no) 2003-12-10
US7186710B2 (en) 2007-03-06
EE200300514A (et) 2004-02-16
BR0209149A (pt) 2004-07-13
PL363312A1 (en) 2004-11-15
BG108294A (bg) 2004-09-30
JP2004526789A (ja) 2004-09-02
CA2445233A1 (fr) 2002-10-31
CN1503792A (zh) 2004-06-09
HUP0303998A2 (hu) 2004-05-28
NZ529221A (en) 2005-04-29
CZ299347B6 (cs) 2008-06-25

Similar Documents

Publication Publication Date Title
SK14342003A3 (sk) Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie
US7179810B2 (en) Phthalazinone-piperidino-derivatives as PDE4 inhibitors
AU2002317733A1 (en) Phthalazinones derivatives useful as PDE4/7 inhibitors
JP2005538138A (ja) Ｐｄｅ４インヒビターとしてのピリダジノン誘導体
US20060166995A1 (en) Piperidine-n-oxide-derivatives
US7022696B2 (en) Piperazino-derivatives and their use as PDE4 inhibitor
AU2002315311A1 (en) Piperazino-derivatives and their use as PDE4 inhibitor
US7820669B2 (en) 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US20080227790A1 (en) Pyridazinone Derivatives and their Use as Pde4 Inhibitors

Legal Events

Date Code Title Description
FC9A Refused patent application